Evaluation of galantamine transbuccal absorption by reconstituted human oral epithelium and porcine tissue as buccal mucosa models: Part I

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 70, Issue 3, 2008, Pages 869-873

  De Caro, Viviana ^a   Giandalia, Giulia ^a   Siragusa, Maria Gabriella ^a   Paderni, Carlo ^a   Campisi, Giuseppina ^a   Giannola, Libero Italo ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Alzheimer's disease; Galantamine; Porcine buccal mucosa; Reconstituted human oral epithelium; Transbuccal permeation

Indexed keywords

GALANTAMINE;

ANIMAL TISSUE; ARTICLE; CHEEK MUCOSA; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG PENETRATION; EVALUATION; EX VIVO STUDY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MOUTH MUCOSA; NONHUMAN; NORMAL HUMAN; SWINE; VALIDATION PROCESS;

ADMINISTRATION, BUCCAL; ANIMALS; CELLS, CULTURED; CHOLINESTERASE INHIBITORS; DIFFUSION; DIFFUSION CHAMBERS, CULTURE; EPITHELIAL CELLS; GALANTAMINE; HUMANS; KINETICS; MOUTH MUCOSA; PERMEABILITY; SWINE;

EID: 54949136459     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2008.06.025     Document Type: Article

References (24)

1. Coyle J., and Kershaw P. Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease. Biol. Psychiatry 49 (2001) 289-299
2. Heinrich M., and Teoh H.L. Galantamine from snowdrop - the development of a modern drug against Alzheimer's disease from local Caucasian knowledge. J. Ethnopharmacol. 92 (2004) 147-162
3. Farlow M.R. Pharmacokinetic profiles of current therapies for Alzheimer's disease: implications for switching to galantamine. Clin. Ther. 23 A (2001) A13-A24
4. Migliaccio-Walle K., Getsios D., Caro J.J., Ishak K.J., O'Brien J.A., and Papadopoulos G. Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States. Clin. Ther. 25 (2003) 1806-1825
5. M.A. Raskind, E.R. Peskind, T. Wessel, W. Yuan, The Galantamine USA - Study Group, Galantamine in AD, A 6-month randomized, placebo-controlled trial with a 6-month extension, Neurology 54 (2000) 2261-2268.
6. Erkinjuntti T. Treatment options: The latest evidence with galantamine (ReminylR). J. Neurol. Sci. 203/204 (2002) 125-130
7. Hao J., and Heng P.W.S. Buccal delivery systems. Drug Dev. Ind. Pharm. 29 (2003) 821-832
8. Rossi S., Sandri G., and Caramella C.M. Buccal drug delivery: a challenge already won?. Drug Discov. Today 2 (2005) 59-65
9. Rathbone M., Drummond B., and Tucker I. The oral cavity as a site for systemic drug delivery. Adv. Drug Deliv. Rev. 13 (1994) 1-22
10. Salamat-Miller N., Chittchang M., and Johnston T.P. The use of mucoadhesive polymers in buccal drug delivery. Adv. Drug Deliv. Rev. 57 (2005) 1666-1691
11. Van Eyk A.D., and van der Bijl P. Comparative permeability of various chemical markers through human vaginal and buccal mucosa as well as porcine buccal and mouth floor mucosa. Arch. Oral Biol. 4 (2004) 387-392
12. Jacobsen J., Nielsen E.B., Brùndum-Nielsen K., Christensen M.E., Olin H.B., Tommerup N., and Rassing M.R. Filter-grown TR146 cells as an in vitro model of human buccal epithelial permeability. Eur. J. Oral Sci. 107 (1999) 138-146
13. Tsutsimii K., Obata Y., Takayama K., Isowa K., and Nagai T. Permeation of several drugs through keratinized epithelial-free membrane of hamster check pouch. Int. J. Pharm. 177 (1999) 7-14
14. Gore A.V., Liang A.C., and Chien Y.W. Comparative biomembrane permeation of tacrine using Yucatan minipigs and domestic pigs as the animal model. J. Pharm. Sc. 87 (1998) 441-447
15. Jacobsen J., van Deurs B., Pedersen M., and Romer Rassing M. TR146 cells grown on filters as a model for human buccal epithelium: morphology, growth, barrier properties, and permeability. Int. J. Pharm. 125 (1995) 165-184
16. Nielesen H.M., and Rassing M.R. TR146 cells grown on filters as a model of human buccal epithelium: IV. Permeability of water, mannitol, testosterone and beta-adrenoceptor antagonists. Comparison to human, monkey and porcine buccal mucosa. Int. J. Pharm. 194 (2000) 155-167
17. Gal J.Y., Fovet Y., and Adib-Yadzi M. About a synthetic saliva for in vitro studies. Talanta 53 (2001) 1103-1115
18. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65 (1983) 55-63
19. Giannola L.I., De Caro V., Giandalia G., Siragusa M.G., Campisi G., Florena A.M., and Ciach T. Diffusion of naltrexone across reconstituted human oral epithelium and histomorphological features. Eur. J. Pharm. Biopharm. 65 (2007) 238-246
20. Giannola L.I., De Caro V., Giandalia G., Siragusa M.G., D'Angelo M., Lo Muzio L., and Campisi G. Transbuccal tablets of carbamazepine: formulation release and absorption pattern. Int. J. Immunopathol. Pharmacol. 18 (2005) 21-31
21. Smart J.D. Lectin-mediated drug delivery in the oral cavity. Adv. Drug Del. Rev. 56 (2004) 481-489
22. Moghadam B.K.H., Hersini S., and Barker B.F. Autoimmune progesterone dermatitis and stomatitis. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 85 (1998) 537-541
23. Neppelberg E., Costea D.E., Vintermyrd O.K., and Johannessen A.C. Dual effects of sodium lauryl sulphate on human oral epithelial structure. Exp. Dermatol. 56 (2007) 574-579
24. Scully C., and Bagan J.V. Adverse drug reactions in the orofacial region. Crit. Rev. Oral Biol. Med. 15 (2004) 221-239